Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures

Kenji Oritani, Xiying Wu, Kay Medina, Jane Hudson, Kensuke Miyake, Jeffrey M. Gimble, Samuel A. Burstein, Paul W. Kincade

Research output: Contribution to journalArticlepeer-review

57 Scopus citations


The KMC8.8 monoclonal antibody was made by immunizing rats with the BMS2 stromal cell clone, and was selected for further study because of its ability to inhibit production of myeloid cells in Dexter cultures but not that of lymphoid cells in Whitlock-Witte cultures. The influence on myeloid progenitors might have been indirect, since the antibody did not prevent responsiveness to colony-stimulating factors in semisolid agar cultures. Furthermore, there was no inhibition, and some augmentation, of cell production when the antibody was added to established Dexter cultures. A cDNA clone that encoded the KMC8.8-recognized molecule was isolated by expression cloning and found to be identical in sequence to a previously published murine CD9 homologue. The antibody and cDNA clone were used to establish that CD9 is expressed by stromal cells, megakaryocytes, platelets, myeloid cells, and subpopulations of mature lymphocytes in mice. Treatment with the KMC8.8/CD9 antibody slightly augmented adhesion between myeloid cells and stromal cells, consistent with previous reports that this member of the tetraspan family of proteins can transmit proadhesive signals to human platelets and lymphoid cells. CD9 might participate in cell-cell interactions critical for correct orientation and movement of maturing myeloid cells in bone marrow.

Original languageEnglish (US)
Pages (from-to)2252-2261
Number of pages10
Issue number6
StatePublished - Mar 15 1996

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'Antibody ligation of CD9 modifies production of myeloid cells in long-term cultures'. Together they form a unique fingerprint.

Cite this